The U.S. Food and Drug Administration is moving to fast-track reviews of two experimental Merck drugs with ...

Merck MRK is expected to face some notable headwinds over the next few years that could affect its long-term growth outlook, ...

The U.S. Food and Drug Administration said on Friday it has granted national priority vouchers to Merck's cholesterol pill ...

Pfizer's Eliquis, a blood thinner and one of its best-selling therapies, will lose patent exclusivity within the next few years. In the meantime, the company's performance leaves a lot to be desired.

Merck & Co. is turning down its option to license Evaxion’s gonorrhea vaccine candidate, closing the door on the Danish ...

The FDA placed the hold after researchers recorded a “higher than anticipated” incidence of deaths in a study testing “I-DXd” ...

Merck declines its option on Evaxion's EVX-B2 gonorrhea vaccine, leaving global rights with Evaxion and no change to its cash ...

“Following the initial pause, the FDA has placed the trial on a partial clinical hold,” the spokesperson explained.

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

We recently published 12 Stocks on Jim Cramer’s Radar . Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s ...

In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new subcutaneous formulation of ...